The influence of elevated concentration of lipids in blood on the concentration of drugs in organism was observed in 1976. The following experiments have revealed that pharmacokinetics of lipophilic drugs in @entity407 is altered. The purpose of this paper was to evaluate the effect of hypolipemic treatment on the @entity1169 pharmacokinetics, to take into account phenotype of hydroxylation and type of primary @entity407 . The study was carried out on 37 @entity1 (34 @entity1 EM and 3 @entity1 PM) with @entity1007 , @entity2298 and mixed form of @entity407 . Duration of hypolipemic therapy was 30 days. Pharmacokinetic studies were carried out twice i.e. at the onset of the study and following a 30-day period of hypolipemic treatment. @entity1169 was given orally as a single dose 80 mg. Blood serum was sampled during administration. HPLC method was used to determine blood serum concentration of @entity1169 . The one-compartment model was applied for calculation of pharmacokinetic parameters. The obtained results have disclosed that hypolipemic therapy altered pharmacokinetic parameters of @entity1169 . Intensity and course of these changes depend on the type of @entity407 . The most pronounced changes were observed in @entity1 EM with @entity2298 . Lowering of @entity1169 concentration in blood, elevated penetration into tissues and accelerated elimination were revealed (Fig. 3, 4). Similar changes, but lesser intensity were observed in @entity1 with mixed form of @entity407 (Fig 5, 6). Alteration of pharmacokinetic parameters of @entity1169 in @entity753 @entity1 were slight and contrasting the @entity1 with @entity2298 and mixed form of @entity407 . The lowering of @entity165 concentration in blood has slight influence on normalization of @entity1169 kinetics (Fig 1, 2). In @entity1 with phenotype PM pharmacokinetic parameters of @entity1169 were changed, under used treatment too. Due to the limited number of @entity1 , conclusions should be carefully drawn. The actual results have disclosed a decrease in lipids concentration, mainly @entity1674 , which causes changes in pharmacokinetics of @entity1169 in @entity1 with phenotype PM as well.

[The effect of hypolipemic treatment on the pharmacokinetics of XXXX ].

@entity407 :: ('MESH:D006949', 'Disease') :: ['hyperlipidemia'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity2298 :: ('MESH:D015228', 'Disease') :: ['hypertriglyceridemia'] @entity1169 :: ('MESH:D011433', 'Chemical') :: ['propranolol', 'Propranolol'] @entity753 :: ('OMIM:143890', 'Disease') :: ['hypercholesterolemic'] @entity1007 :: ('MESH:D006937', 'Disease') :: ['hypercholesterolemia'] @entity1674 :: ('MESH:D014280', 'Chemical') :: ['triglycerides'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']
@entity1169 :: (MESH:D011433,Chemical) :: ['propranolol']
